The need to protect intellectual property (IP) via patents has become an increasingly vital concern for the design process, business strategy, worth, and growth of all medical device companies, from garage-based start-ups to large publicly held companies. And, as the need for innovative, cost-effective technologies in health care has surged, so has the current and projected patent activity in this space, influenced in part by the recent significant changes in the US patent system under the America Invents Act (AIA). In fact, the number of device patents issued grew at a 15.7% rate between 2010 and 2012, with 60,300 patents assigned during this time period, according to the newly released fourth annual "State of Innovation" report by business information and news provider Thomson Reuters. What's more, the device category exhibited the strongest growth rate of the 12 key technology areas examined using the Thomson Reuters Derwent World Patents Index (DWPISM) database.
Medical Device Patents Surging, Industry Players Forecast The Future
With recent changes to US patent laws, a landmark US Supreme Court decision, and the emergence of so-called “patent trolls” in the medical device community, it seems everyone is talking patents. Medical device patents and litigation are “booming,” according to industry experts, and medtech companies need to pay close attention.
More from Legal & IP
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
A planned merger between medical device coating manufacturers Surmodics and Biocoat is facing an antitrust lawsuit from the US Federal Trade Commission. The FTC believes the move would create an illegal monopoly.
An attorney representing the ACLA in its lawsuit to stop the US FDA’s final rule on LDTs emerged from a lengthy hearing on the case feeling ‘cautiously optimistic’ and said a decision could come before May.
More from Policy & Regulation
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.